PVP-Guided Decongestive Therapy in HF 2

Launched by BAŞAKŞEHIR ÇAM & SAKURA CITY HOSPITAL · Jul 3, 2024

Keywords

ClinConnect Summary

This clinical trial, called PVP-Guided Decongestive Therapy in HF 2, is exploring a new way to help patients with heart failure manage their condition better. Researchers believe that measuring peripheral venous pressure (PVP) – which looks at the pressure in your veins – could help doctors predict how much medication (diuretics) you might need to reduce fluid buildup. This could lead to better long-term health outcomes, like fewer hospital visits and improved survival rates.

To participate in this trial, you need to be between 18 and 99 years old and have been hospitalized for heart failure, whether it’s a new case or a worsening of a previous condition. However, if you have certain medical issues, like severe kidney problems or specific heart conditions, you may not be eligible. If you join the study, you can expect to receive care that focuses on monitoring your PVP, which could help tailor your treatment plan more effectively. The trial is currently looking for participants, so this could be a great opportunity to contribute to important research while receiving specialized care.

Gender

ALL

Eligibility criteria

• • Inclusion criteria
• • Hospitalization for heart failure (de novo or decompensated chronic heart failure) irrespective of left ventricular ejection fraction
• • Age 18-99
• • Accept to participate
• • Exclusion criteria
• • A prior history of upper extremity venous disease
• • Serum creatinine ≥ 3.5 mg/dL
• • Severe stenotic valvular disease
• • Hypertrophic obstructive cardiomyopathy
• • Withdrawal of consent
• • Indwelling central venous catheter,
• • Implanted left ventricular assist device
• • History of heart transplantation
• • Clinical diagnosis of cardiogenic shock
• • Any right-to-left shunt